Translarna

PTC Therapeutics, Inc. (NASDAQ: PTCT) traded sigificantly higher Monday after having published a positive update from its risdiplam trial in type 1 SMA babies. The Rating William Blair analyst Raju Prasad accordingly upgraded PTC to Outperform. The Thesis Risdiplam’s efficacy data compares...

PTC Therapeutics, Inc. (NASDAQ: PTCT) is already experiencing some major volatility Tuesday ahead of its upcoming AdCom meeting for Duchenne muscular dystrophy drug candidate Translarna on Thursday. The stock took a 22-percent dive Tuesday morning ahead of the meeting as investors have started to...

Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) soared more than 80 percent higher on Friday. The company confirmed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the renewal of the company's therapy called Translarna (ataluren...

Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) soared higher by nearly 90 percent early Friday morning after the company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the renewal of the company's therapy called...

PTC Therapeutics, Inc. (NASDAQ: PTCT) shares received a big boost Monday, thanks to positive tidings received by Sarepta Therapeutics Inc. (NASDAQ: SRPT). The latter received FDA's accelerated approval for eteplirsen for treating exon 51 skipping amenable Duchenne's muscular dystrophy....

PTC Therapeutics, Inc. (NASDAQ: PTCT) provided an update on July 25 regarding its discussions with European regulators and the path forward with the FDA, in association with Translarna. Wedbush’s Heather Behanna maintains a Neutral rating on the company, while lowering the price target from $...

Oppenheimer said the recent recommendation from NICE for Translarna is a "turning point" for PTC Therapeutics, Inc. (NASDAQ: PTCT) shares, as it bodes well for the upcoming CHMP review. The Importance Of Translarna To PTC On Friday, shares of PTC Therapeutics surged more than 40 percent after it...

It’s been about six weeks since Credit Suisse initiated coverage of PTC Therapeutics, Inc. (NASDAQ: PTCT) with an Outperform rating and $36 price target on the stock. Now, less than two months later, the stock is down more than 76 percent and trading at $5.70 per share. On February 23, PTC...

Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) were down as much as 2 percent in the pre-market hours Tuesday following the U.S. FDA questioning the effectiveness of Translarna in nonsense mutation Duchenne muscular dystrophy (nmDMD). PTC was notified that negative results from both Phase-2b and...

Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) spiked higher by more than 7 percent on Friday, but are still lower by nearly 35 percent year-to-date. The company reported results from a Phase 3 ACT DMD clinical trial of Translarna on Thursday. Debjit Chattopadhyay of Roth Capital maintained a...